New Injection Therapy Offers Hope for Parkinson’s Patients in Phoenix, AZ
Jul 17, 2025
A groundbreaking Parkinson’s disease therapy, ABBV-951, offers continuous dopamine replacement via subcutaneous injection. This blog explores how this innovative treatment could change the landscape of Parkinson’s care in Phoenix, Arizona, and what it means for patients at the Center for Neurology and Spine.
At the Center for Neurology and Spine (CNS), we are committed to bringing cutting-edge care to our community. As leading Arizona neurology specialists, we’re excited to spotlight a revolutionary Parkinson’s disease therapy making headlines in recent neurology research: ABBV-951, a continuous subcutaneous infusion of foslevodopa/foscarbidopa.
This new injectable formulation could transform Parkinson’s disease treatment—especially for patients in Phoenix seeking alternatives to oral levodopa/carbidopa regimens that often lose effectiveness over time. Here's what you need to know about this promising advancement in Parkinson’s care and how it could affect patients at our Phoenix neurology center.
ABBV-951 is a subcutaneously administered prodrug formulation of levodopa and carbidopa, known as foslevodopa and foscarbidopa. These active agents convert into standard L-DOPA and carbidopa within the body. However, unlike traditional oral Parkinson’s therapies, ABBV-951 provides continuous 24-hour dopaminergic stimulation—mimicking the body’s natural rhythm far more closely than pills.
According to a recent study published in Journal of Controlled Release (July 2025), ABBV-951 significantly reduced motor fluctuations in moderate to advanced Parkinson’s disease patients while avoiding many of the challenges associated with gastrointestinal absorption.
Patients at our Phoenix neurology clinic often report increasing difficulties with symptom control as Parkinson’s progresses. Motor fluctuations—periods where medication wears off and symptoms return—are common and debilitating. ABBV-951 offers:
Improved symptom stability: Continuous delivery smooths out peaks and troughs associated with oral dosing.
Non-invasive administration: The injection is given subcutaneously (under the skin), avoiding complex surgeries like deep brain stimulation (DBS).
Better tolerability: This delivery bypasses the gut, which can be impaired in Parkinson’s disease.
If you or a loved one are seeking advanced Parkinson’s treatment in Phoenix AZ, our team at CNS is evaluating emerging therapies, including those like ABBV-951.
The study observed:
Stable plasma levels of L-DOPA and carbidopa over 24 hours.
Rapid onset within minutes of subcutaneous infusion.
Sustained dopamine coverage comparable or superior to oral dosing.
Favorable safety profile: Common side effects included mild injection site reactions, but serious adverse events were rare.
This trial lays the groundwork for real-world application of continuous dopamine infusion in outpatient settings across Arizona.
For patients in Phoenix managing advanced Parkinson’s disease, options beyond pills have been limited. ABBV-951 may provide an alternative for those who:
Experience frequent “off” periods.
Have difficulty swallowing or digesting medication.
Cannot undergo surgery for deep brain stimulation.
The treatment may also benefit patients seeking more predictable symptom management as they age—especially important in Arizona’s older adult population.
As one of the best neurologist teams in Phoenix, CNS is proud to lead the region in Parkinson’s disease treatment and clinical research. We provide comprehensive evaluations, medication management, EMG testing Phoenix, EEG testing Phoenix AZ, and access to cutting-edge clinical trials.
Whether you’re newly diagnosed or exploring second-line therapies, our board-certified Parkinson’s specialists in Phoenix offer personalized care strategies, including referrals for advanced therapies like ABBV-951 once FDA approved.
We also work closely with patients' primary care providers to ensure holistic support—from neurodiagnostic testing Arizona to memory clinic Phoenix services.
Q: Is ABBV-951 currently available in Phoenix?
A: Not yet—it’s still undergoing trials and regulatory review, but CNS is closely monitoring its progress for future implementation.
Q: Who might be a candidate for ABBV-951?
A: Patients with moderate to advanced Parkinson’s who experience motor fluctuations despite optimized oral therapy.
Q: Does CNS offer similar therapies now?
A: We offer DBS referrals, oral and transdermal medications, and we are evaluating participation in future trials related to continuous infusion therapies.
At CNS, we believe innovation should be accessible. As Arizona neurology research studies evolve, so too do our services. We are proud to provide advanced neurology care Arizona residents can trust—whether it’s Parkinson’s disease, Alzheimer’s disease treatment Arizona, migraine treatment Phoenix AZ, or epilepsy care Phoenix.
For families seeking a neurologist near me or a second opinion from a dementia specialist Arizona, CNS delivers science-backed, compassionate care.
Stay tuned as we continue expanding our services and research offerings at our Phoenix neurology center—including opportunities to participate in upcoming Parkinson’s trials.
If you or someone you love is living with Parkinson’s and exploring advanced treatment options in Arizona, schedule an appointment with a Parkinson’s specialist Phoenix trusts. Call Center for Neurology and Spine today at [CNS Phone Number] or visit www.centerforneurologyandspine.com.
#ParkinsonsPhoenix
#NeurologistPhoenixAZ
#ArizonaNeurologySpecialists
#BrainHealthArizona
#ContinuousDopamineTherapy
#PhoenixNeurologyCenter
#NeurologicalDisordersPhoenix
#ParkinsonsTreatmentArizona
#CNSResearchAZ
#AdvancedNeurologyCareArizona
#PhoenixAgingBrain
#NeurogeneticsArizona
#NeuroimmunologyClinicPhoenix
#MemoryClinicPhoenix
#ABBV951Parkinsons